11/20
12:50 pm
ivvd
Invivyd, Inc. (NASDAQ: IVVD) had its price target lowered by analysts at Morgan Stanley from $9.50 to $3.55. They now have an "overweight" rating on the stock.
Low
Report
Invivyd, Inc. (NASDAQ: IVVD) had its price target lowered by analysts at Morgan Stanley from $9.50 to $3.55. They now have an "overweight" rating on the stock.
11/20
08:06 am
ivvd
Invivyd, Inc. (NASDAQ: IVVD) had its price target lowered by analysts at HC Wainwright from $15.00 to $10.00. They now have a "buy" rating on the stock.
Medium
Report
Invivyd, Inc. (NASDAQ: IVVD) had its price target lowered by analysts at HC Wainwright from $15.00 to $10.00. They now have a "buy" rating on the stock.
11/19
01:23 pm
ivvd
High Growth Tech Stocks To Explore In November 2024 [Yahoo! Finance]
Low
Report
High Growth Tech Stocks To Explore In November 2024 [Yahoo! Finance]
11/18
01:29 pm
ivvd
High Growth Tech Stocks in the United States to Watch [Yahoo! Finance]
Low
Report
High Growth Tech Stocks in the United States to Watch [Yahoo! Finance]
11/18
09:34 am
ivvd
Exploring 3 High Growth Tech Stocks in the United States [Yahoo! Finance]
Low
Report
Exploring 3 High Growth Tech Stocks in the United States [Yahoo! Finance]
11/15
02:22 am
ivvd
Invivyd Inc (IVVD) Q3 2024 Earnings Call Highlights: Strong Revenue and Strategic Growth Amidst ... [Yahoo! Finance]
Medium
Report
Invivyd Inc (IVVD) Q3 2024 Earnings Call Highlights: Strong Revenue and Strategic Growth Amidst ... [Yahoo! Finance]
11/14
07:15 am
ivvd
Invivyd Reports Third Quarter 2024 Financial Results and Recent Business Highlights [Yahoo! Finance]
High
Report
Invivyd Reports Third Quarter 2024 Financial Results and Recent Business Highlights [Yahoo! Finance]
11/14
07:05 am
ivvd
Invivyd Reports Third Quarter 2024 Financial Results and Recent Business Highlights
High
Report
Invivyd Reports Third Quarter 2024 Financial Results and Recent Business Highlights
11/14
07:04 am
ivvd
Invivyd Announces New England Journal of Medicine Publishes Letter to the Editor Highlighting Immunobridging Pathway Leading to PEMGARDA™ (pemivibart) Emergency Use Authorization; Comments on Adjacent Third-Party Letter to the Editor [Yahoo! Finance]
High
Report
Invivyd Announces New England Journal of Medicine Publishes Letter to the Editor Highlighting Immunobridging Pathway Leading to PEMGARDA™ (pemivibart) Emergency Use Authorization; Comments on Adjacent Third-Party Letter to the Editor [Yahoo! Finance]
11/14
07:01 am
ivvd
Invivyd Announces New England Journal of Medicine Publishes Letter to the Editor Highlighting Immunobridging Pathway Leading to PEMGARDA™ (pemivibart) Emergency Use Authorization; Comments on Adjacent Third-Party Letter to the Editor
High
Report
Invivyd Announces New England Journal of Medicine Publishes Letter to the Editor Highlighting Immunobridging Pathway Leading to PEMGARDA™ (pemivibart) Emergency Use Authorization; Comments on Adjacent Third-Party Letter to the Editor
11/13
01:26 pm
ivvd
High Growth Tech Stocks to Watch in November 2024 [Yahoo! Finance]
Low
Report
High Growth Tech Stocks to Watch in November 2024 [Yahoo! Finance]
11/13
09:41 am
ivvd
High Growth Tech Stocks To Explore In November 2024 [Yahoo! Finance]
Medium
Report
High Growth Tech Stocks To Explore In November 2024 [Yahoo! Finance]
11/13
07:37 am
ivvd
Invivyd Inc (IVVD) Q3 2024 Earnings Report Preview: What to Expect [Yahoo! Finance]
High
Report
Invivyd Inc (IVVD) Q3 2024 Earnings Report Preview: What to Expect [Yahoo! Finance]
11/12
01:32 pm
ivvd
High Growth Tech Stocks Featuring Three Prominent US Companies [Yahoo! Finance]
Neutral
Report
High Growth Tech Stocks Featuring Three Prominent US Companies [Yahoo! Finance]
11/12
09:34 am
ivvd
Exploring 3 High Growth Tech Stocks in the United States [Yahoo! Finance]
Low
Report
Exploring 3 High Growth Tech Stocks in the United States [Yahoo! Finance]
11/12
08:30 am
ivvd
Invivyd Announces Preprints Conveying CANOPY Phase 3 Clinical Trial Data Including Long-Term Protection Versus Recent JN.1 Sublineages at Low Residual Titers, and Describing a Novel Approach for Predicting Monoclonal Antibody Activity Were Uploaded to Med
Medium
Report
Invivyd Announces Preprints Conveying CANOPY Phase 3 Clinical Trial Data Including Long-Term Protection Versus Recent JN.1 Sublineages at Low Residual Titers, and Describing a Novel Approach for Predicting Monoclonal Antibody Activity Were Uploaded to Med
11/11
01:29 pm
ivvd
Exploring Three High Growth Tech Stocks in the United States [Yahoo! Finance]
Medium
Report
Exploring Three High Growth Tech Stocks in the United States [Yahoo! Finance]
11/8
01:18 pm
ivvd
Exploring High Growth Tech Stocks In November 2024 [Yahoo! Finance]
Low
Report
Exploring High Growth Tech Stocks In November 2024 [Yahoo! Finance]
11/8
09:33 am
ivvd
High Growth Tech Stocks In The US To Watch [Yahoo! Finance]
Medium
Report
High Growth Tech Stocks In The US To Watch [Yahoo! Finance]
11/6
08:01 am
ivvd
Invivyd to Participate in the Guggenheim Securities Healthcare Innovation Conference
Medium
Report
Invivyd to Participate in the Guggenheim Securities Healthcare Innovation Conference
11/6
07:01 am
ivvd
Invivyd to Host Third Quarter 2024 Financial Results and Corporate Update Conference Call on November 14, 2024
High
Report
Invivyd to Host Third Quarter 2024 Financial Results and Corporate Update Conference Call on November 14, 2024
11/1
07:24 am
ivvd
Invivyd, Inc. (NASDAQ: IVVD) was upgraded by analysts at EF Hutton Acquisition Co. I to a "strong-buy" rating.
Low
Report
Invivyd, Inc. (NASDAQ: IVVD) was upgraded by analysts at EF Hutton Acquisition Co. I to a "strong-buy" rating.
10/29
02:09 pm
ivvd
Invivyd, Inc. (NASDAQ: IVVD) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $15.00 price target on the stock.
Low
Report
Invivyd, Inc. (NASDAQ: IVVD) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $15.00 price target on the stock.
10/29
07:12 am
ivvd
Invivyd Reports Preliminary Third Quarter 2024 Results, Withdraws Prior Financial Guidance, and Targets Near-Term Profitability [Yahoo! Finance]
High
Report
Invivyd Reports Preliminary Third Quarter 2024 Results, Withdraws Prior Financial Guidance, and Targets Near-Term Profitability [Yahoo! Finance]
10/29
07:06 am
ivvd
Invivyd Phase 3 Long-Term Exploratory Clinical Efficacy Data Shows PEMGARDA™ (pemivibart) Provided Substantial Protection from Symptomatic COVID-19 Versus Placebo Over Six Months of Follow-Up, With No Additional Doses, In Immunocompetent Participants [Yah
Medium
Report
Invivyd Phase 3 Long-Term Exploratory Clinical Efficacy Data Shows PEMGARDA™ (pemivibart) Provided Substantial Protection from Symptomatic COVID-19 Versus Placebo Over Six Months of Follow-Up, With No Additional Doses, In Immunocompetent Participants [Yah